Han Koh, MD
Payments from drug & device makers
Across 503 payments — averaging $19.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$1K
- AstraZeneca$1K
- Novartis$966
- AbbVie$856
- Amgen$550
- Lilly USA, LLC$502
- plus $5K from 29 others
What the payments were for
- Food & beverage$9,42997%
- Education$2623%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 130 | $1,142 |
| AstraZeneca(2 entities) | 43 | $1,071 |
| Novartis | 60 | $966 |
| AbbVie | 45 | $856 |
| Amgen(2 entities) | 26 | $550 |
| Lilly USA, LLC | 23 | $502 |
| E.r. Squibb & Sons, L.L.C. | 10 | $470 |
| Teva Pharmaceuticals USA, Inc. | 24 | $456 |
| Biogen | 20 | $434 |
| Sanofi | 26 | $428 |
| Biohaven Pharmaceuticals, Inc. | 13 | $348 |
| Eisai Inc. | 10 | $347 |
| Pfizer | 22 | $325 |
| Acadia Pharmaceuticals Inc | 6 | $264 |
| Neurocrine Biosciences, Inc. | 10 | $234 |
| SK Life Science, Inc. | 2 | $181 |
| Harmony Biosciences LLC | 2 | $145 |
| TG Therapeutics, Inc. | 2 | $114 |
| Argenx US, Inc. | 2 | $84 |
| Sunovion Pharmaceuticals Inc. | 4 | $82 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $77 |
| Vanda Pharmaceuticals Inc. | 2 | $74 |
| Impel Pharmaceuticals Inc. | 1 | $70 |
| EMD Serono, Inc. | 1 | $62 |
| Jazz Pharmaceuticals Inc. | 1 | $57 |
| Sanofi-aventis U.S. LLC | 3 | $55 |
| Lundbeck LLC | 1 | $53 |
| UCB, Inc. | 1 | $52 |
| Mallinckrodt Enterprises LLC | 2 | $40 |
| Axsome Therapeutics, Inc. | 1 | $37 |
| Inspire Medical Systems, Inc. | 1 | $27 |
| ANI Pharmaceuticals, Inc. | 1 | $25 |
| Supernus Pharmaceuticals, Inc. | 2 | $25 |
| Mallinckrodt Hospital Products Inc. | 1 | $23 |
| Strongbridge US Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$115
- XCOPRI$112
- NUPLAZID$105
How this compares
$9,691 in reported general payments places this provider in the 70th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 112 | $1,033,613 |
| ZeposiaOzanimod Hydrochloride | 30 | $270,659 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 16 | $230,137 |
| IngrezzaValbenazine Tosylate | 12 | $97,452 |
| TecfideraDimethyl Fumarate | 11 | $97,006 |
| Teriflunomide | 22 | $94,767 |
| CopaxoneGlatiramer Acetate | 12 | $69,064 |
| Nurtec OdtRimegepant Sulfate | 39 | $52,824 |
| XcopriCenobamate | 29 | $31,664 |
| NeuproRotigotine | 23 | $25,434 |
| Emgality PenGalcanezumab-Gnlm | 34 | $23,842 |
| RexultiBrexpiprazole | 15 | $21,023 |
| Aimovig AutoinjectorErenumab-Aooe | 25 | $18,723 |
| Ajovy SyringeFremanezumab-Vfrm | 20 | $14,926 |
| UbrelvyUbrogepant | 18 | $14,449 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Zeposia | $470 | $270,65930 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $234 | $97,45212 claims |
| BiogenTecfidera | $434 | $97,00611 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $456 | $69,06412 claims |
| PfizerNurtec Odt | $325 | $52,82439 claims |
| SK Life Science, Inc.Xcopri | $181 | $31,66429 claims |
| UCB, Inc.Neupro | $52 | $25,43423 claims |
| AbbVieUbrelvy, Savella | $856 | $19,47729 claims |
| Axsome Therapeutics, Inc.Sunosi | $37 | $9,38311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 941 neurology providers in Pennsylvania.
Other neurology in Sayre
- David WeismanAbington$9.3M
- Amit Bar-OrPhiladelphia$7.7M
- Thomas LeistPhiladelphia$5.8M
- Jan DrappatzPittsburgh$4M
- Lauren ElmanPhiladelphia$3.3M
- David IrwinPhiladelphia$2.5M
- Paula ClemensPittsburgh$2.1M
- Anoopum GuptaPittsburgh$2M
- Daniel KremensPhiladelphia$1.9M
- Frances JensenPhiladelphia$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.